These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

766 related items for PubMed ID: 25875942

  • 1. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK, de Oliveira Cipriano Torres D, dos Santos Gomes FO, dos Santos Silva B, Lima Ribeiro E, Costa Oliveira A, dos Santos LA, de Lima Mdo C, Pitta Ida R, Peixoto CA.
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [Abstract] [Full Text] [Related]

  • 2. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S, Soares E Silva A, Gomes F, Ribeiro E, Oliveira W, Oliveira A, Lima I, Lima MDC, Pitta I, Peixoto C.
    Eur J Pharmacol; 2016 Oct 05; 788():306-314. PubMed ID: 27349145
    [Abstract] [Full Text] [Related]

  • 3. Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).
    Soares E Silva AK, de Oliveira Cipriano Torres D, Santos Rocha SW, dos Santos Gomes FO, dos Santos Silva B, Donato MA, Raposo C, Santos AC, de Lima Mdo C, Galdino SL, da Rocha Pitta I, de Souza JR, Peixoto CA.
    Cardiovasc Pathol; 2013 Oct 05; 22(1):81-90. PubMed ID: 22795892
    [Abstract] [Full Text] [Related]

  • 4. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
    Zaitone SA, Barakat BM, Bilasy SE, Fawzy MS, Abdelaziz EZ, Farag NE.
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun 05; 388(6):587-600. PubMed ID: 25708949
    [Abstract] [Full Text] [Related]

  • 5. Chronic LPSF/GQ-02 treatment attenuates inflammation and atherosclerosis development in LDLr-/- mice.
    Silva AKSE, Gomes FODS, Santos Silva BD, Ribeiro EL, Oliveira AC, Araújo SMDR, de Lima IT, Oliveira AGV, Rudnicki M, Abdalla DSP, Lima MDCA, Pitta IDR, Peixoto CA.
    Eur J Pharmacol; 2016 Nov 15; 791():622-631. PubMed ID: 27693798
    [Abstract] [Full Text] [Related]

  • 6. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
    Elshazly SM.
    Eur J Pharmacol; 2015 Feb 05; 748():123-32. PubMed ID: 25542756
    [Abstract] [Full Text] [Related]

  • 7. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
    Nozaki Y, Fujita K, Wada K, Yoneda M, Kessoku T, Shinohara Y, Imajo K, Ogawa Y, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
    BMC Gastroenterol; 2015 Apr 01; 15():42. PubMed ID: 25881230
    [Abstract] [Full Text] [Related]

  • 8. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC, Liu BQ, Chen J, De J, Nima ZB, Dunzhu CR.
    J Ethnopharmacol; 2019 May 23; 236():316-325. PubMed ID: 30851372
    [Abstract] [Full Text] [Related]

  • 9. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
    He Q, Zeng J, Yao K, Wang W, Wu Q, Tang R, Xia X, Zou X.
    Biochem Biophys Res Commun; 2020 Nov 12; 532(3):362-369. PubMed ID: 32883523
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
    van der Veen JN, Lingrell S, Gao X, Quiroga AD, Takawale A, Armstrong EA, Yager JY, Kassiri Z, Lehner R, Vance DE, Jacobs RL.
    Am J Physiol Gastrointest Liver Physiol; 2016 Apr 01; 310(7):G526-38. PubMed ID: 26797396
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution.
    Nozaki Y, Fujita K, Wada K, Yoneda M, Shinohara Y, Imajo K, Ogawa Y, Kessoku T, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
    BMC Gastroenterol; 2015 Dec 17; 15():177. PubMed ID: 26678309
    [Abstract] [Full Text] [Related]

  • 13. Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study.
    Heeba GH, El-Deen RM, Abdel-Latif RG, Khalifa MMA.
    Can J Physiol Pharmacol; 2020 Aug 17; 98(8):498-505. PubMed ID: 32083947
    [Abstract] [Full Text] [Related]

  • 14. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
    Tsujimoto S, Kishina M, Koda M, Yamamoto Y, Tanaka K, Harada Y, Yoshida A, Hisatome I.
    Int J Mol Med; 2016 Sep 17; 38(3):721-8. PubMed ID: 27431935
    [Abstract] [Full Text] [Related]

  • 15. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG, An XS.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):416-423. PubMed ID: 29454967
    [Abstract] [Full Text] [Related]

  • 16. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y, Chen L, Wang H, Narisi B, Chen B.
    J Ethnopharmacol; 2015 Dec 24; 176():499-507. PubMed ID: 26571089
    [Abstract] [Full Text] [Related]

  • 17. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
    Li X, Wang Z, Klaunig JE.
    Toxicology; 2019 Mar 15; 416():1-14. PubMed ID: 30711707
    [Abstract] [Full Text] [Related]

  • 18. Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
    Guo CH, Chen WL, Liao CH, Huang K, Chen PY, Yang CP.
    Int J Med Sci; 2018 Mar 15; 15(11):1194-1202. PubMed ID: 30123057
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, Chang KC.
    Eur J Pharmacol; 2016 Oct 05; 788():200-209. PubMed ID: 27343380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.